安立生坦对合并肺动脉高压的慢性阻塞性肺疾病的疗效观察

发布时间：2018-02-01 19:30

本文关键词： 安立生坦慢性阻塞性肺疾病肺动脉高压　出处：《中国医院药学杂志》2014年20期 　论文类型：期刊论文

【摘要】：目的:观察安立生坦对合并肺动脉高压(PH)的慢性阻塞性肺疾病(COPD)的疗效。方法:将42例合并PH的COPD患者分为安立生坦组(组A)和对照组(组B),每组21例,组A在常规治疗的基础上加用安立生坦,5 mg,口服,每天一次,连续治疗6个月,记录治疗前后第1秒用力呼气容积(forced expiratory volume in 1 second,FEV1)、用力肺活量(forced vital capacity,FVC)、动脉血气氧分压(PO2)、二氧化碳分压(PCO2)、谷草转氨酶(AST)、谷丙转氨酶(ALT)、N端脑钠肽前体(NT-ProBNP)、肺动脉收缩压(PASP)。结果:治疗后A组的FEV1、FVC、PO2较B组明显升高,PCO2、NT-Pro-BNP和PASP较组B明显降低,2组的AST、ALT无显著性差异。结论:安立生坦能显著改善合并PH的COPD患者的通气功能、心功能及肺动脉压力。
[Abstract]:Objective: to observe the therapeutic effect of Anlishantan on chronic obstructive pulmonary disease (COPD) complicated with pulmonary hypertension (PH). Methods: 42 patients with COPD complicated with PH were divided into two groups (group A). And control group (group B). There were 21 cases in each group. Group A was treated for 6 months with the addition of 5 mg of ANL on the basis of routine treatment. Forced expiratory volume in 1 second FEV1 before and after treatment were recorded. Forced vital capacity (vital), arterial partial pressure of oxygen (PO2), partial pressure of carbon dioxide (PCO2), glutamic oxaloacetic transaminase (AST). The precursor of N-terminal brain natriuretic peptide (NT-ProBNPN), pulmonary arterial systolic pressure (PAP) and pulmonary artery systolic pressure (PASP). Results: after treatment, FEV1 FVC in group A was treated with glutamate-alanine aminotransferase (alt). Compared with group B, PO2 was significantly higher than that of group B in NT-Pro-BNP and PASP. Compared with group B, AST in group B was significantly lower than that in group B. Conclusion: Anlisentan can significantly improve the ventilation function, cardiac function and pulmonary artery pressure in COPD patients with PH.
【作者单位】：武汉市第一医院重症监护室;
【分类号】：R544.1;R563.9
【正文快照】： 慢性阻塞性肺疾病(COPD)是临床上常见的一种严重的呼吸道疾病。肺动脉高压(PH)是COPD的并发症之一,其发生原因与慢性缺氧导致肺血管收缩和肺血管重塑有关。PH会增加患者右心的后负荷,长期的后负荷过重会导致右心功能衰竭,降低合并PH的COPD患者的肺动脉压力至关重要,其不仅可以

【参考文献】